Business Wire

New US Patent for Solidia Technologies’ CO2-cured Concrete Advances Performance and Sustainability of Building Materials

Jaa

The U.S. Patent and Trademark Office issued a patent for the structure of CO2-cured Solidia Concrete™, advancing the performance and sustainability of materials available to the global construction and materials industries. Solidia Technologies® holds the exclusive licensing rights to the patent, which is held by Rutgers University, where the original generation of the material was invented.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180119005608/en/

Solidia Concrete™ pavers. (Photo: Business Wire)

Solidia Concrete™ pavers. (Photo: Business Wire)

U.S. Patent No. 9,868,667, "Bonding Element, Bonding Matrix and Composite Material Having the Bonding Element and Method of Manufacturing Thereof," covers the composition of matter of the non-hydraulic concrete.

“The hydrate bonds in conventional concrete can compromise that material’s strength and durability,” explained Solidia Chief Technology Officer Nicholas DeCristofaro, Ph.D. “With CO2-cured concrete, bonding elements based on silica and calcium carbonate create a wide range of attractive properties, including mechanical strength, resistance to freeze-thaw deterioration, and resistance to sulfate attack.”

Solidia addresses the cement industry’s goal of reducing its carbon emissions, which contribute 3-5% of global CO2 pollution. Solidia’s processes start with an energy-saving, sustainable cement, then cure concrete with CO2, reduce the carbon footprint of cement and concrete up to 70%, and recycle 60 to 80% of the water used in production. Using the same raw materials and existing equipment as traditional concretes, the resulting products are higher performing, cost less to produce, and cure in less than 24 hours.

“Our next-generation concrete offers a competitive edge to the global US$1 trillion concrete and US$300 billion cement markets, advancing profitability and sustainability in an industry that needs both,” said Solidia President and CEO Tom Schuler.

Currently in commercialization for large- and small-scale applications, the initial technology focus was on unreinforced precast applications, including pavers and blocks. Solidia is now developing processes for reinforced applications, including aerated concrete, railroad ties, architectural panels and hollow core extrusions.

Solidia’s patent estate includes over 200 patent applications worldwide, with 32 issued and 14 scheduled. Investors include Kleiner Perkins Caufield & Byers, Bright Capital, BASF, BP, LafargeHolcim, Total Energy Ventures, Air Liquide, OGCI Climate Investments, Bill Joy and other private investors.

Follow Solidia Technologies at www.solidiatech.com and on LinkedIn, YouTube and Twitter: @SolidiaCO2.

Contact information

YUI+Company, Inc.
Ellen Yui, 301-270-8571
ellenyui@yuico.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Takeda Receives Clearance from the European Commission for the Proposed Acquisition of Shire plc20.11.2018 17:33Tiedote

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has received clearance from the European Commission (the “EC”) for the proposed acquisition of Shire plc (“Shire”) announced on May 8, 2018 (the “Acquisition”). The EC’s approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance. Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda’s marketed product Entyvio (vedolizumab) and Shire’s pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights. The divestment of SHP647 and certain associated rights is not a condition to the completion of the Acquisition. SHP647 is an exciting pipeline compound

ResMed Elects Harjit Gill to Its Board of Directors20.11.2018 17:05Tiedote

ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service business solutions, today announced it has elected experienced consumer and healthcare executive Harjit Gill to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005179/en/ Harjit Gill, BA (Photo: Business Wire) Ms. Gill was elected by shareholders at its annual shareholder meeting last week in Sydney, Australia. Also, announced at that meeting, Gary W. Pace has retired from ResMed’s board after serving on it since July 1994. Ms. Gill’s appointment and Dr. Pace’s retirement both took effect Thursday, November 15. Ms. Gill has more than 25 years’ experience in health and consumer technology products as an executive, investor and regional business leader spanning Asia, Europe and the Middle East. From 1990 to 2015, she worked for Royal Philips as executive vice president and CEO for Phi

PTC Adds Artificial Intelligence and Generative Design Capabilities to Enhance and Expand its CAD Portfolio with Acquisition of Frustum20.11.2018 15:12Tiedote

PTC (NASDAQ: PTC) today announced that it has acquired Frustum Inc., an advanced generative design software company, for approximately $70 million. Frustum’s technology for generative design—an approach that leverages artificial intelligence (AI) to generate design options—is a transformative addition to the PTC Creo portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005326/en/ PTC Adds Artificial Intelligence and Generative Design Capabilities to Enhance and Expand its CAD Portfolio with Acquisition of Frustum (Graphic: Business Wire) Based in Boulder, Colorado, Frustum offers patented desktop and cloud-based engineering software that enables designers and engineers to go beyond the limits of their personal experience by leveraging powerful AI capabilities that guide the discovery of high-performance, next-generation product designs. “PTC is pushing the boundaries of innovation with this acquisition,” said Jim

United First Partners Launches UFP Fintech20.11.2018 15:00Tiedote

United First Partners (“UFP”), a leading independent Research, Brokerage, Advisory & Investment group is pleased to announce the launch of its latest venture: UFP Fintech. UFP Fintech invests in early stage Fintech, Proptech and Legaltech startups. Under the leadership of the entity’s CIO Christophe Petetin, a veteran investor in the Fintech space with an unparalleled investment track record in Fintech start-ups, UFP Fintech aims to become a global leader in Early Stage Fintech Investments. In recent years, Christophe and the UFP Fintech team have seeded a major unicorn and several other market leading entities. Christophe is a premier Fintech thought leader, who also acts in an advisory capacity to governmental and regulatory bodies, such as the FCA and ISO 20022 to create the next generation of standards for Fintech, payments, data, securities & digital currencies. Christophe commented “The financial industry is getting rebuilt from the ground up creating unprecedented opportunities.

LEO Pharma and PellePharm Announce $760 Million Collaboration to Advance Innovative Therapies for Rare Skin Diseases20.11.2018 14:00Tiedote

Danish dermatology specialists LEO Pharma and California rare disease pioneers PellePharm today announced a strategic development and commercialization collaboration to address unmet medical needs across various skin diseases with no approved treatments, advancing innovation and access to potential therapies for patients with life-altering conditions, such as Gorlin Syndrome and High Frequency Basal Cell Carcinoma (BCC), two distinct and rare forms of skin cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005227/en/ “We are very excited about the partnership with PellePharm, who are pioneers in Gorlin Syndrome and experts in rare skin diseases. Supporting our ambitious 2025 strategy, it marks LEO Pharma’s entrance in rare skin diseases and it offers a unique opportunity to bring the first treatment forward to people suffering from a very severe skin disease for which there currently are no approved therapies,” sai

IDEMIA Provides SK Telecom in South Korea with GMSA Compliant Smart Connect Solution to Activate and Manage eSIM Device Lifecycles20.11.2018 12:00Tiedote

IDEMIA, the global leader in Augmented Identity, is proud to have been selected by SK Telecom, the number one telecommunication operator in South Korea, to launch the first eSIM Connected watch based on GSMA Consumer standards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005231/en/ Crédits : IDEMIA As a leading actor in the telecom field, IDEMIA is at the forefront of the digital revolution and is committed to bringing protected and convenient experiences to mobile operator customers. Leveraging its industrial leadership and appetite for innovation, IDEMIA will be providing SK Telecom its GSMA compliant solution. Based on IDEMIA’s Smart Connect Subscription management solution also known as remote SIM provisioning, the technology remotely connects the eSIM of the smart watch to the SK Telecom’s network without inserting a physical SIM card. This technology is also compliant with the latest GSMA standards ensuring in

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme